alopecia

Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia

Stem Cell and Platelet Rich Plasma Alopecia

2021-2027 Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

The research team projects that the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries.

Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts.

The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Orange County Hair Restoration Center
Colorado Surgical Center & Hair Institute
Evolution Hair Loss Institute
Hair Sciences Center of Colorado
Hair Transplant Institute of Miami
Anderson Center for Hair
Virginia Surgical Center
Savola Aesthetic Dermatology Center

By Type

Platelet Rich Plasma Injections
Stem Cell Therapy

By Application

Dermatology Clinics
Hospitals

By Regions/Countries:

North America
United States
Canada
Mexico
East Asia
China
Japan
South Korea
Europe
Germany
United Kingdom
France
Italy
Russia
Spain
Netherlands
Switzerland
Poland
South Asia
India
Pakistan
Bangladesh
Southeast Asia
Indonesia
Thailand
Singapore
Malaysia
Philippines
Vietnam
Myanmar
Middle East
Turkey
Saudi Arabia
Iran
United Arab Emirates
Israel
Iraq
Qatar
Kuwait
Oman
Africa
Nigeria
South Africa
Egypt
Algeria
Morocoo
Oceania
Australia
New Zealand
South America
Brazil
Argentina
Colombia
Chile
Venezuela
Peru
Puerto Rico
Ecuador
Rest of the World
Kazakhstan

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and their impact on the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with the company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with the base year as 2020.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further the report provides break down details about each region & countries covered in the report.

Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers the majority of Product Types in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis by Application Type: Based on the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry and its applications, the market is further sub-segmented into several major Applications of its industry. It provides you with the market size, CAGR & forecast by each industry application.

Market Trends: Market key trends include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis:

The report will provide the state of competition in the industry depends on five basic forces: the threat of new entrants, bargaining power of suppliers, bargaining power of buyers, the threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact

The report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency.

The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in 2021. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

2021-2027 Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia

Stem Cell and Platelet Rich Plasma Alopecia

2021-2027 Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

The research team projects that the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries.

Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts.

The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Orange County Hair Restoration Center
Colorado Surgical Center & Hair Institute
Evolution Hair Loss Institute
Hair Sciences Center of Colorado
Hair Transplant Institute of Miami
Anderson Center for Hair
Virginia Surgical Center
Savola Aesthetic Dermatology Center

By Type

Platelet Rich Plasma Injections
Stem Cell Therapy

By Application

Dermatology Clinics
Hospitals

By Regions/Countries:

North America
United States
Canada
Mexico
East Asia
China
Japan
South Korea
Europe
Germany
United Kingdom
France
Italy
Russia
Spain
Netherlands
Switzerland
Poland
South Asia
India
Pakistan
Bangladesh
Southeast Asia
Indonesia
Thailand
Singapore
Malaysia
Philippines
Vietnam
Myanmar
Middle East
Turkey
Saudi Arabia
Iran
United Arab Emirates
Israel
Iraq
Qatar
Kuwait
Oman
Africa
Nigeria
South Africa
Egypt
Algeria
Morocoo
Oceania
Australia
New Zealand
South America
Brazil
Argentina
Colombia
Chile
Venezuela
Peru
Puerto Rico
Ecuador
Rest of the World
Kazakhstan

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and their impact on the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with the company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with the base year as 2020.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further the report provides break down details about each region & countries covered in the report.

Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers the majority of Product Types in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis by Application Type: Based on the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry and its applications, the market is further sub-segmented into several major Applications of its industry. It provides you with the market size, CAGR & forecast by each industry application.

Market Trends: Market key trends include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis:

The report will provide the state of competition in the industry depends on five basic forces: the threat of new entrants, bargaining power of suppliers, bargaining power of buyers, the threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact

The report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency.

The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in 2021. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

2021-2027 Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Source

Recent Posts

CTP-543 THRIVE Clinical Program

CTP-543 THRIVE Clinical Program

The Patient Recruiting Agency, LLC Announces Enrollment Launched for the CTP-543 THRIVE Clinical Program Investigating Oral Treatment for Moderate to Severe Alopecia Areata

The Patient Recruiting Agency™ announces open enrollment for the THRIVE Clinical Program, a series of clinical trials exploring the investigational product CTP-543 for the potential oral treatment of moderate to severe alopecia areata. CTP-543 is being developed by Concert Pharmaceuticals, Inc.

The purpose of the ongoing THRIVE Clinical Program is to measure the effect of CTP-543 on hair regrowth and to evaluate safety in people with alopecia areata.

The THRIVE Clinical Program is now enrolling adults 18 to 65 years old with at least 50% scalp hair loss due to alopecia areata. The current episode of hair loss must have lasted at least 6 months and no longer than 10 years. The total time a person has had alopecia areata may exceed 10 years.

Following a 24-week treatment period, participants will have the opportunity to enrol into an open-label extension study in which all participants will receive an active dose of CTP-543.

The THRIVE Clinical Program is being conducted at multiple research study centres throughout the United States and Canada. For more information about this important clinical research study, please visit our study website.

CTP-543 is a selective Janus kinase (JAK) inhibitor intended to disrupt the process that causes hair follicles to be incorrectly targeted by the body’s immune system. There are currently no FDA-approved treatments for alopecia areata.

US Thrive Clinical Program Website: https://www.mythrivestudy.com

Canadian Thrive Clinical Program Website: https://www.mythrivestudy.ca

About The Patient Recruiting Agency™

Located in Austin, Texas, The Patient Recruiting Agency™ (TPRA) supports Sponsors, CROs, SMOs, and Investigators with patient recruitment services.

The Patient Recruiting Agency, LLC Announces Enrollment Launched for the CTP-543 THRIVE Clinical Program Investigating Oral Treatment for Moderate to Severe Alopecia Areata

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment

Market Research Report 2021-2027

The Global Alopecia Treatment Market poised to grow from US$ XX million in 2021 to US$ XX million by 2027 at a compound annual growth rate (CAGR) of XX% during the projection period of 2021-2027.

The report states that the Alopecia Treatment market condition and market forces acting across the industry. Analysts use the most recent primary and secondary research techniques and tools to arrange comprehensive and accurate marketing research reports. The research study also includes other types of analysis such as qualitative and quantitative.

All proportion of shares and breakdowns are determined using secondary sources and verified primary sources. The report could be a collection of first-hand info, qualitative and quantitative assessment by industry analysts, and industry participants across the value chain.

COVID-19 Impact Evaluation

This report also analyses the impact of Coronavirus COVID-19 on the Xxx industry.

Based on our recent survey, we have several different scenarios about the Xxx YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Xxx will reach xx in 2026, with a CAGR of xx% from 2021 to 2027.

Market Dynamics:

The research report provides analysis and information according to market segments such as geographies, product type, application, and end-use industry. Featuring worldwide and over leading key player profiles, this report serves the ultimate guide to exploring opportunities in the Alopecia Treatment industry globally.

The Alopecia Treatment market report provides effective guidelines and strategies for industry players to secure a position at the top in the worldwide Alopecia Treatment market. Our experts have added large key companies who play an important role in the sales, and distribution of the products. The significant applications and potential business arenas are also added to this report. It encourages the client to make strategic moves and create their businesses.

Moreover, the Alopecia Treatment market report includes information on major product categories, their demand, supply, developments, recent product approvals regulatory scenario and competitive intelligence. The regional scope of the report covers major geographical market places; North America, Europe, Asia-Pacific, Latin America and the Middle East along with market numbers, and growth potential in form of forecast market values in US$ million. Furthermore, the report also sheds light on the competitive landscape in the industry, talking about the key industry participants, their products and services, strategies, financial information and their positions in the market.

The Alopecia Treatment market report covers the following key industry participants:

Teva Pharmaceutical Industries
Merck
Johnson&Johnson
Reddy’s Laboratories
Cipla
Cellmid
Himalaya Drug
Taisho Pharmaceutical Holdings

The Alopecia Treatment Market is divided into product, application and regional market.

The product segment of the report offers product market information such as demand, supply and market value of the product.

The application of the product in terms of US$ value is represented in numerical and graphical format for all the major regional markets.

The Alopecia Treatment market report is segmented into Type by the following categories;

Topical Drugs
Oral Drugs
Injectable
Hair Transplant Services
Other

The Alopecia Treatment market report is segmented into Application by following categories;

Hospitals
Dermatology And Trichology Clinics
Home Care Settings
Other

Above information is further split with respect to following geographies;

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Russia
Asia Pacific
China
Japan
India
South Korea
Australia
Middle East and Africa
Saudi Arabia
UAE
South Africa
South America
Brazil
Argentina

Key Information and data offered by the Alopecia Treatment market report:

Market definition, scope and assumptions

Market drivers, restraints, opportunity and challenges

Product market value and future projections in US$ million

Tabular and graphical representation of numbers and growth trend

Alopecia Treatment market estimated in terms of the market size in US$ million and forecast for product, application and regional market

The growth potential and forecast information for Global Alopecia Treatment Market and for segments, by region and by country.

The report includes competitive analysis of the Alopecia Treatment market comprising of key industry players profile. The company profiles offer company overview, business summary, product information, recent development and strategic outlook.

Global Alopecia Treatment Market Research Report 2021-2027

Source

Recent Posts

Phase 2a trial evaluating CTP-543

Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA1 in 2022. A second Phase 3 trial, THRIVE-AA2, is expected to begin in the first half of 2021.

“Based on the results from our Phase 2 program, we believe CTP-543 has the potential to offer patients a best-in-class treatment for moderate to severe alopecia areata,” said James V. Cassella, Ph.D., Chief Development Officer, Concert Pharmaceuticals. “We are fully committed to advancing CTP-543 with its Breakthrough Therapy designation in order to make a meaningful difference in the lives of individuals impacted by alopecia areata.”

The initiation of THRIVE-AA1 follows an end-of-phase 2 meeting where Concert discussed key aspects of its Phase 3 program and registration strategy with the U.S. Food and Drug Administration (FDA). The end-of-phase 2 meetings with the FDA was held following positive results from a dose-ranging Phase 2 trial of CTP-543 in patients with moderate to severe alopecia areata. Under current timelines, the Company believes that positive results from two Phase 3 trials could serve as the basis for submitting a New Drug Application in early 2023 for CTP-543 for the treatment of moderate to severe alopecia areata in adult patients.

“There are millions of people around the world affected by and living with alopecia areata,” said Andy Bryant, Acting Chief Executive Officer of the National Alopecia Areata Foundation. “We’re encouraged by CTP-543’s potential to be one of the first FDA-approved medicines to treat alopecia areata.”

About the THRIVE-AA1 Study

THRIVE-AA1 (NCT04518995) is a randomized, double-blind, placebo-controlled clinical trial in adult patients with moderate to severe alopecia areata at sites in the U.S., Canada and Europe evaluating the regrowth of scalp hair after 24 weeks of dosing using the Severity of Alopecia Tool (SALT). Key aspects of THRIVE-AA1 include:

  • Patient characteristics: adults age 18-65 years with ≥ 50% hair loss are eligible for the study;
  • Expected enrollment size: approximately 700 patients;
  • Dosing: 8 mg twice-daily or 12 mg twice-daily of CTP-543 or placebo for 24 weeks; and
  • Primary endpoint: Percent of patients achieving a SALT score ≤ 20 at Week 24.

For more information about the THRIVE-AA1 study, please visit https://clinicaltrials.gov/ct2/show/NCT04518995.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Source

Recent Posts

Alopecia Treatment Market

Global Alopecia Market Insights

Global Alopecia Market Insights and Forecast to 2026

Alopecia market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Alopecia market will be able to gain the upper hand as they use the report as a powerful resource.

The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Alopecia market is segmented into

Oral treatment
Topical treatment
Other treatment

Segment by Application, the Alopecia market is segmented into

Male
Female

Regional and Country-level Analysis

The Alopecia market is analysed and market size information is provided by regions (countries).

The key regions covered in the Alopecia market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes a country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Alopecia Market Share Analysis

Alopecia market competitive landscape provides details and data information by players. The report offers a comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020.

It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Alopecia business, the date to enter into the Alopecia market, Alopecia product introduction, recent developments, etc.

The major vendors covered:

Lifes2good
Kirkland Signature
Johnson & Johnson
Dr Reddys Laboratories.
Cipla.
Alpecin.
Vitabiotics.
Sun Pharma.
Phyto Ales Group

Global Alopecia Market Insights and Forecast to 2026

Source

Previous Posts

Arena Starts Phase II Alopecia Areata Study on Etrasimod

Arena Starts Phase II Alopecia Areata Study on Etrasimod

Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod

Arena Pharmaceuticals, Inc. ARNA announced that it has dosed first patients in a phase II study to evaluate its key pipeline candidate — etrasimod — as a potential treatment for moderate-to-severe alopecia areata. The study will evaluate the 2mg dose of the candidate for efficacy and safety over 24 weeks.

The primary endpoint of the phase II study is the percent change in the Severity of Alopecia Tool (“SALT”) score from baseline. Data from the study is anticipated in 2021.

The candidate has demonstrated the potential to reduce inflammation and restore hair growth in earlier stage studies.

Shares of Arena have gained 50.5% year to date compared with the industry’s increase of 2.7%.

Alopecia areata is an autoimmune dermatologic condition that results in patchy non-scarring hair loss, usually affecting the scalp. There is no FDA approved drug presently available to treat this condition, which can lead to high levels of depression and anxiety in patients.

Pfizer PFE is another company developing an oral JAK3 inhibitor candidate, PF-06651600 for Alopecia areata in a pivotal study.

Apart from alopecia areata, Arena is developing etrasimod in other indications as well. The candidate is presently in late-stage development for ulcerative colitis (“UC”).

Arena is currently enrolling patients in two pivotal phase III studies — ELEVATE UC 52 and ELEVATE UC 12 — evaluating etrasimod for treating moderately-to-severely active UC.

A phase IIb study — ADVISE — is evaluating etrasimod in patients with atopic dermatitis (“AD”). Data from the study is expected later this year. Another phase IIb study — CULTIVATE — was initiated earlier this year to evaluate the candidate in Crohn’s disease. The company has plans to start a mid-stage study to evaluate the candidate for eosinophilic esophagitis, a gastro-intestinal disease by year-end.

Arena has another key pipeline candidate, olonarib. The phase II CAPTIVATE study is evaluating olaparib as a treatment for abdominal pain associated with irritable bowel syndrome. Data from the study is expected later this year.

We note that Arena is progressing well with its key pipeline candidates. However, the company will face stiff competition from multiple approved drugs in their targeted indications.

There are several drugs approved for treating UC including AbbVie’s ABBV multi-billion dollar drug, Humira. Sanofi/Regeneron’s REGN Dupixent is one of the top drugs approved for treating AD.

Moreover, olaparib, following potential approval, will compete with AbbVie/Ironwood Pharma’s Linzess.

Arena (ARNA) Starts Phase II Alopecia Areata Study on Etrasimod

Source

Previous Posts

Global Alopecia Treatment Industry Research Report

Alopecia Market

Alopecia Market

Market Summary

The Alopecia Market is expected to reach USD 12.99 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with the rising predominance of chronic disorders such as hyperthyroidism, hypothyroidism, acute stress disorder, lupus, and hypo pituitarism.

Moreover, increasing incidence of Hodgkin’s disease, Hashimoto’s disease, Addison’s disease, and celiac disease along with factors such as access to treatment quickly are expected to drive the market growth.

However, the high cost of treatment and adverse side effects is expected to restrain the growth. Also, changing lifestyle such as consumption of tobacco, an increase in the use of alcohol, and other associated products, growing stress levels, and the expanding population are expected to spur the market. Increasing disposable incomes coupled with expanding emphasis on aesthetic appearance are also likely to add to the demand for alopecia treatment worldwide.

Hair loss, also acknowledged as alopecia or baldness refers to a loss of hair from part of the head. The typical pattern of hair loss can vary from a small area to the entire body. Scarring or inflammation is not present. Hair loss in some people may cause psychological distress.

General types include female-pattern hair loss, male-pattern hair loss, alopecia areata, and a thinning of hair also known as telogen effluvium. The cause of male-pattern hair loss is a combination of male hormones and genetics, the purpose of female pattern hair loss is not clear, the use of alopecia areata is auto-immune, and the cause of telogen effluvium is mostly a psychological or physically stressful event.

The rising number of the introduction of new drugs, consumer disposable incomes, and the complementary initiatives taken by the relevant organizations namely, AHLA and NAAF, are the crucial factors for the North America region to account for the largest market share of 22.30% in 2018.

Key Coverage of the Report

Region and country wise statistics of Alopecia Market from the period 2016-2026. While 2016-2017 has been utilized as historical data, 2018 is considered the base year. 2019-2026 have been derived as forecasts.
Estimation of the market size along with historic and forecasted trend analysis.
Various Cure Types of Alopecia Market technique have been analyzed. Statistical analysis has been conducted on obtaining the individual share of these segments.
Regional up-coming Alopecia Market outlook.
Regional prevalence of the market has been mapped.
Demand and Supply GAP Analysis
Regional Competitors Pricing Strategy
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments.

Salient Trends of the Alopecia Market

The market is projected to grow at a CAGR of 1% in terms of value and reach USD 12.99 billion in 2026.
Based on disease type, the alopecia market is classified into androgenetic alopecia, alopecia areata (AA), and others. Androgenetic type led this market in 2018 with the largest revenue of USD 3.65 billion in 2018 and is expected to grow at a favorable rate over the forecast period.
Alopecia areata is an autoimmune skin disease identified by hair loss on the scalp, face, and other areas of the body. Alopecia areata is segmented into totalis, patchy, and universalis further.
The rising predominance of alopecia areata owing to autoimmune diseases such as diabetes, hyperthyroidism, and Down’s syndrome is expected to drive demand over the forecast period.
Increasing predominance coupled with rising awareness regarding aesthetic appeal and physical appearance is also assumed to drive market growth in the next few years.
Alopecia areata is expected to be the fastest-growing market with a CAGR of 5.2% during the forecast period.
Steroid injections may treat alopecia areata in the affected area, but these need to be continuously repeated to be effective. Hair loss is a common problem. The pattern of hair loss by age 50 affects about half of males and a quarter of females. About 1-2% of people develop alopecia areata at some point in time.
Male-Pattern Hair Loss (MPHL) or Androgenetic alopecia is associated with various medical conditions such as diabetes, coronary heart disease, obesity, prostate cancer, hypertension, and Polycystic Ovary Syndrome (PCOS).
Also, the availability of treatments such as oral treatments, licensed topical treatments involving the use of finasteride and minoxidil; and surgical procedures such as hair replacement and transplantation are expected to drive the market.
Laser treatments are also becoming common for non-invasive approach. Such non-invasive treatment approaches are also likely to drive the androgenetic segment.
The global Alopecia Market is growing at a rapid speed owing to the increase in stress and changed lifestyle.
The market can be classified into home care settings and dermatology clinics, based on application. Dermatology clinics account for the largest market share of 54.24% in 2018 and are anticipated to grow at a fruitful rate over the forecast period.
Dermatology clinics coupled with innovative technologies and prescription hair care products help many affected individuals fight their condition.
Consultation with dermatologists is regarded as the best option for the treatment, as they prescribe suitable medication or therapy for effective results. These factors are responsible for the high need for dermatology clinics for hair loss treatment.
On the other hand, treatment in home care settings is expected to grow at a rate of 5.1% during the forecast period.
Prescription medicine segment is anticipated to grow owing to increasing disposable income and quickly changing lifestyle. Finasteride and Corticosteroids are some of the majorly prescribed medications.
Based on the sales distribution, the market is segmented into prescription-based medications or treatment devices and Over the Counter (OTC).
Sale of prescription products account for the larger market share of 68.85% in 2018 and is estimated to reach USD 5.95 billion by 2026.
The OTC segment is expected to grow at a rate of 5.1% during the forecast period.
Increasing R&D efforts to improve treatments, FDA approvals obtained for certain products and strategic initiatives taken by the key players, are the primary competitive strategies paving the way for market expansion.
In April 2016, Johnson & Johnson announced the launch of a new global healthcare initiative to implement healthcare solutions, in Africa.
The developing prosperity of countries such as Indonesia, Taiwan, China, and India is inviting new international ventures in these countries thereby leading to the growth of various industries in the APAC region.

Companies considered and profiled in this market study

Cipla Inc., Johnson and Johnson AG, Transitions Hair Pty Ltd., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc.,  Cirrus Hair Centers, Lexington International LLC,  Vita-Cos-Med Klett-Loch GmbH, Follica, Inc., and Capillus.

Market-O-Nomics

Rising demand for low-cost treatment, growing awareness regarding adverse effects of prescribed drugs, and the increasing availability of options are spurring the need for OTC products.
Moreover, a surge in the number of FDA-approved OTC products for hair loss treatments is additionally expanding their demand. Some of the FDA-approved OTC products for hair loss treatment are Oscar Blandi hair lift instant thickening and strengthening serum and Keranique hair regrowth system.
In 2018, the dominant gender segment for the alopecia market is women that accounts for the larger market share of 56.48%. The growing awareness amongst women about alopecia and the importance laid upon appearance by them are the key drivers of this segment.
Due to the predominance of a vast number of new entrants, established manufacturers, and suppliers in the market, the industry is extremely competitive.
Asia Pacific is forecasted to witness the fastest CAGR of 5.4% during the forecast period. A vast population suffering from alopecia and growing awareness about the available therapeutic options are the key growth drivers.
Economic development coupled with continually increasing per capita healthcare investment in emerging countries such as India, China, and Singapore is expected to create high growth opportunities.
Innovations and technological trends in treatment, evolving healthcare expenditures, and increased healthcare facilities are expected to drive the growth further.

Segments Covered in the report:

This report forecasts revenue growth at a global, regional & country level, and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2026.

For the purpose of this study, Reports and Data have segmented the global Alopecia Market on the basis of Disease, Gender, application, Sales distribution and region:

Disease Outlook (Revenue, USD Million; 2016-2026)

Alopecia Areata
Androgenetic Alopecia
Others

Sales distribution Outlook (Revenue, USD Million; 2016-2026)

Prescriptions
OTC

Application Outlook (Revenue, USD Million; 2016-2026)

Homecare Settings
Dermatology Clinics

Gender Outlook (Revenue, USD Million; 2016-2026)

Female
Male

Regional Outlook (Revenue, USD Million; 2016-2026)

North America
U.S.
Europe
Germany
UK
Asia Pacific
China
India
Southeast Asia
Latin America
Brazil
Middle East & Africa

Source

Previous Posts

Alopecia Treatment Market

Trial for Androgenic Alopecia

Histogen Announces Completion of Patient Enrollment for its HST 001 Phase 1b/2a Trial for Androgenic Alopecia

Histogen a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the completion of patient enrollment ahead of schedule in its Phase 1b/2a clinical trial of HST 001, designed to assess the safety, tolerability and indicators of efficacy of HST 001 for the treatment of androgenic alopecia in men.

“We are pleased to have accomplished this clinical milestone with HST 001 and we look forward to completing the treatment phase of the study and releasing top-line data in the fourth quarter of this year,” said Richard W. Pascoe, Histogen’s President and CEO. “The on-time achievement of this milestone demonstrates our ability to execute on the clinical development plans for HST 001, which has the potential to stimulate new long-lasting hair growth in contrast to existing therapies that focus on reducing hair loss.”

About the HST 001 Phase 1a/2b Trial
This blinded, randomized, placebo-controlled, single-site study has enrolled 36 subjects with male pattern hair loss using a 2:1 randomization of HST 001 to placebo.

It is designed to assess the safety and tolerability of HST 001, as well as indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography.

At each treatment time point (Weeks 0, 6, and 12), subjects will receive a total of 20 injections divided between the temporal recession and vertex scalp areas, the most common regions of hair loss in men with androgenic alopecia.

Primary endpoints will be assessed at Week 18 and secondary endpoints at both Week 18 and Week 26. Top-line data is anticipated to be available in the fourth quarter of 2020.

About HST 001

HST 001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. We expect HSC to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss.

HSC is designed to enrich for growth factors including KGF, VEGF and follistatin, which are involved in signalling stem cells in the body and have been shown to be important in hair formation and the stimulation of resting hair follicles.

About Histogen

Histogen is a regenerative medicine company developing patented technologies that replace and regenerates tissues in the body. The company’s innovative technology platform utilizes cell-conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address underserved, multi-billion US dollar global markets.

For more information, please visit www.histogen.com.

Histogen Announces Completion of Patient Enrollment for its HST 001 Phase 1b/2a Trial for Androgenic Alopecia in MenTop Line Results Expected Q4’2020

Source

Recent Posts

Global Alopecia Treatment

Global Alopecia Treatment

Global Alopecia Treatment

Global Alopecia Treatment (Hair Loss) Market is expected to rise from its initial estimated value of USD 8.21 billion in 2018 to an estimated value of USD 12.40 billion by 2026 registering a CAGR of 5.3% in the forecast period of 2019-2026.

This rise in the market can be attributed to the rising geriatric population along with high demand for surgical hair transplant and changing lifestyle.

This Alopecia Treatment (Hair Loss) market analysis report profiles leading companies of the market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

The study includes information on key segmentation of the global Alopecia Treatment (Hair Loss)  market on the basis of type/product, application and geography (country/region).

Each of the segments included in the report is studied in relation to different factors such as market size, market share, value, growth rate and other quantitative information.

The competitive analysis included in this Alopecia Treatment (Hair Loss) market study allows readers to understand the difference between players and how they are operating among themselves on a global scale.

Few of the major market competitors currently working in the alopecia treatment (hair loss) market are

Cipla,

Viviscal,

Dr Reddy’s Laboratories Ltd.,

Regaine,

Merck & Co., Inc,

Ranbaxy Laboratories Ltd,

Phyto – Alès Groupe,

Kirkland Signature,

Vitabiotics,

Nanogen,

Key Developments in the Market:

In January 2018, Concert Pharmaceuticals, Inc. announced U.S. FDA granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, a disease which attacks the hair follicles, leading to hair loss.

In May 2018, Histogen, Inc (U.S.) announced that received approval to Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to study its lead product in female diffuse hair loss.

In March 2017, Perrigo Perrigo Company PLC (U.S.) announced the launch of over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Table Of Content:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Global Alopecia Treatment (Hair Loss) Market Landscape

Part 04: Global Alopecia Treatment (Hair Loss) Market Sizing

Part 05: Global Alopecia Treatment (Hair Loss) Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework
Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Global Alopecia Treatment

Source

Recent Posts

Alopecia Treatment Market

Alopecia Treatment Market

Global Alopecia Treatment Market Size Share Forecast 2025

Alopecia also called as hair loss or baldness is a very common condition affecting people across the globe. Alopecia can affect people of all gender and at any stage of life, it generally it affects mid-aged generation. For instance, according the data published by Arch Argent Pediatr in 2017, the prevalence of Alopecia areata is high in the age group of 10 and 25 years and around 60% of people under these age group suffer from Alopecia areata.

Market Dynamics

Product launches, approvals, and a robust pipeline of novel products is expected to be the major driver of the growth of the global alopecia treatment market. For instance, in 2016, Cellmid Limited, a wholly-owned subsidiary, Advangen Limited launched new hair loss product évolis in U.S. market.

In May 2018, Histogen, Inc., received the approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to study its lead product Hair Stimulating Complex (HSC660) in female diffuse hair loss. HSC660 is an investigational injectable treatment for alopecia and is expected to get FDA approval in the near future. Key players in the market are engaged in strategic collaborations for increasing geographic presence in the market.

For instance, in May 2018, Cellmid Limited signed a collaborative agreement with Beijing Fukangren Bio-pharm Tech Co Ltd. for distribution of its product in the Peoples Republic of China. Furthermore, the increasing prevalence of alopecia worldwide is expected to drive the growth of the market.

According to the data published by National Center for Biotechnology Information (NCBI), in 2015, androgenetic alopecia is a most prevalent autoimmune disorder and the second most prevalent hair loss disorder and around 2% population worldwide is suffering from androgenetic alopecia.

Key features of the study:

• This report provides in-depth analysis of alopecia treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year

• It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

• It profiles leading players in the global alopecia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans

• Key companies covered as a part of this study include Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Daiichi Sankyo, Inc., Cipla Limited, and others.

• Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

• The global alopecia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the alopecia treatment market

Detailed Segmentation:

• Global Alopecia Treatment Market, By Disease Type :

o Androgenic Alopecia
o Alopecia Areata
o Ciatricial Alopecia
o Traction Alopecia
o Alopecia Totalis

• Global Alopecia Treatment Market, By Drug Type:

o Vasodilators
o Minoxidil
o 5-Alpha Reductase Inhibitors
o Finasteride
o Corticosteroids
o Immunosuppressants
o Cyclosporine
o Others
o Others

• Global Alopecia Treatment Market, By Gender:

o Male
o Female

• Global Alopecia Treatment Market, By Route of Administration:

o Oral
o Topical
o Injectable

• Global Alopecia treatment market, By Distribution Channel:

o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies

• Global Alopecia treatment market, By Geography:

Global Alopecia Treatment Market Size Share Forecast 2025

Source

Recent Posts